JPMorgan Chase & Co. Sells 155,390 Shares of Capricor Therapeutics, Inc. $CAPR

JPMorgan Chase & Co. lowered its position in Capricor Therapeutics, Inc. (NASDAQ:CAPR) by 45.0% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 189,799 shares of the biotechnology company’s stock after selling 155,390 shares during the quarter. JPMorgan Chase & Co.’s holdings in Capricor Therapeutics were worth $1,368,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Pier Capital LLC boosted its holdings in Capricor Therapeutics by 35.0% in the 3rd quarter. Pier Capital LLC now owns 496,554 shares of the biotechnology company’s stock worth $3,580,000 after buying an additional 128,837 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Capricor Therapeutics by 39.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock worth $3,902,000 after buying an additional 116,373 shares during the period. Two Sigma Investments LP boosted its holdings in Capricor Therapeutics by 128.3% in the 3rd quarter. Two Sigma Investments LP now owns 355,796 shares of the biotechnology company’s stock worth $2,565,000 after buying an additional 199,959 shares during the period. Jump Financial LLC boosted its holdings in Capricor Therapeutics by 42.6% in the 2nd quarter. Jump Financial LLC now owns 232,536 shares of the biotechnology company’s stock worth $2,309,000 after buying an additional 69,515 shares during the period. Finally, GSA Capital Partners LLP bought a new position in Capricor Therapeutics in the 3rd quarter worth $1,555,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Stock Down 1.2%

Shares of CAPR stock opened at $31.60 on Thursday. The stock has a market cap of $1.82 billion, a P/E ratio of -13.98 and a beta of 0.48. Capricor Therapeutics, Inc. has a 52 week low of $4.30 and a 52 week high of $40.37. The company’s fifty day simple moving average is $27.91 and its two-hundred day simple moving average is $19.63.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.11). On average, analysts anticipate that Capricor Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on CAPR shares. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of Capricor Therapeutics in a report on Tuesday, March 10th. UBS Group set a $50.00 target price on shares of Capricor Therapeutics in a report on Monday, December 15th. Wall Street Zen downgraded shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, January 11th. Piper Sandler reaffirmed an “overweight” rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. Finally, Cantor Fitzgerald set a $62.00 target price on shares of Capricor Therapeutics and gave the stock an “overweight” rating in a report on Friday, March 13th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Capricor Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $46.09.

Insider Buying and Selling at Capricor Therapeutics

In other Capricor Therapeutics news, Director Karimah Es Sabar sold 7,529 shares of the business’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $32.00, for a total value of $240,928.00. Following the sale, the director owned 7,529 shares in the company, valued at $240,928. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Anthony Bergmann sold 25,000 shares of the business’s stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $30.13, for a total transaction of $753,250.00. Following the completion of the sale, the chief financial officer owned 8,223 shares in the company, valued at approximately $247,758.99. The trade was a 75.25% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 147,529 shares of company stock worth $4,509,940. Corporate insiders own 10.50% of the company’s stock.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.